<DOC>
	<DOCNO>NCT00463008</DOCNO>
	<brief_summary>RATIONALE : Collecting fluid brain tumor use small catheter may help doctor learn much methotrexate get tumor kill tumor cell . It may also help doctor learn methotrexate work brain rest body . PURPOSE : This clinical trial study much methotrexate get brain tumor collect fluid directly tumor small catheter patient undergoing stereotactic biopsy recurrent high-grade glioma .</brief_summary>
	<brief_title>Pharmacologic Study Methotrexate Patients Undergoing Stereotactic Biopsy Recurrent High-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility use microdialysis study distribution systemically administer methotrexate interstitial fluid within tumor patient undergoing stereotactic biopsy recurrent high-grade glioma . - Determine systemic intratumoral pharmacokinetics drug patient . OUTLINE : This multicenter study . Patients intratumoral microdialysis catheter place undergoing stereotactic biopsy . Between 18-32 hour placement catheter , patient receive methotrexate IV 4 hour . Microdialysis perfusate blood specimen collect , , 24 hour methotrexate administration . Patients follow 2 week . PROJECTED ACCRUAL : A total 12 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial grade III IV astrocytoma 1 follow subtypes : Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Measurable , contrastenhancing , residual disease MRI CT scan Undergoing stereotactic biopsy confirmation tumor progression differentiation tumor progression treatmentinduced effect Patients prior lowgrade glioma progress prior radiotherapy without chemotherapy need stereotactic biopsy confirm highgrade glioma eligible Must receive prior radiotherapy without chemotherapy Planning continue methotrexate therapy participation study No ascites pleural effusion PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 2.0 mg/dL SGOT ≤ 4 time upper limit normal Creatinine ≤ 2 mg/dL Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ Able achieve hydration necessary use methotrexate Mini mental state exam score least 15 No allergy methotrexate No concurrent infection medical illness would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 3 month since prior radiotherapy At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) At least 1 week since prior salicylate , nonsteroidal antiinflammatory drug , sulfonamides No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent chemotherapeutic agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
</DOC>